Immunology and Bi...
Follow
Find
5.9K views | +7 today
 
Scooped by Gilbert Faure au nom de l'ASSIM from Institut Pasteur de Tunis-معهد باستور تونس
onto Immunology and Biotherapies
Scoop.it!

Medical History

Medical History | Immunology and Biotherapies | Scoop.it

Via Seth Dixon, Institut Pasteur de Tunis - معهد باستور تونس‎
Gilbert Faure au nom de l'ASSIM's insight:

but nowadays, researchers spend much time to get money to work.... and to learn and on the other hand, biotherapies market is skyrocketting!

more...
Seth Dixon's curator insight, December 13, 2013 11:31 AM

I found this on social media (unfortunately I don't have an original source to link to fo documentation) and was greatly impressed by the information here, but also the historical implications of this information.  Could/would this happen today?  How would the world be different is this was the 'new normal?'  How would the world be different if this never did happen?

Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humoral and cell-mediated immune responses elicited by poly (DL-lac... - PubMed - NCBI

Drug Deliv. 2014 May;21(3):233-41. doi: 10.3109/10717544.2013.848494. Epub 2013 Oct 30.
Gilbert Faure au nom de l'ASSIM's insight:

a filarial adjuvant

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498, Expert Opinion on Therapeutic Patents, Informa Healthcare

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498, Expert Opinion on Therapeutic Patents, Informa Healthcare | Immunology and Biotherapies | Scoop.it
L is for CLL treatments #AntibodyAtoZ Check out our review of anti-CD44 antibody for B-cell leukemia http://t.co/922YdzsVQe @DrugPatentWatch
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antibody Therapies Entering 2015 - Total Biopharma : Total Biopharma

Antibody Therapies Entering 2015 - Total Biopharma : Total Biopharma | Immunology and Biotherapies | Scoop.it
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Virology and Bioinformatics from Virology.ca
Scoop.it!

Virology Journal | Full text | Plant-based vaccines against viruses

Plant-made or “biofarmed” viral vaccines are some of the earliest products of the technology of plant molecular farming, and remain some of the brightest prospects for the success of this field. Proofs of principle and of efficacy exist for many candidate viral veterinary vaccines; the use of plant-made viral antigens and of monoclonal antibodies for therapy of animal and even human viral disease is also well established. This review explores some of the more prominent recent advances in the biofarming of viral vaccines and therapies, including the recent use of ZMapp for Ebolavirus infection, and explores some possible future applications of the technology.

Via Chris Upton + helpers
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal? (MGNX) - Seeking Alpha

B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal? (MGNX) - Seeking Alpha | Immunology and Biotherapies | Scoop.it

Checkpoint inhibitors are a big deal. What started with ipilimumab has now grown into a class of drugs which are being pursued vigorously by nearly every major pharmaceutical company in the world. In this crowded space, it's worth noting that B7-H3 is only being pursued by one company, MacroGenics (NASDAQ:MGNX).


Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Journal of Investigative Dermatology - Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Journal of Investigative Dermatology - Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes | Immunology and Biotherapies | Scoop.it
The Journal of Investigative Dermatology publishes basic and clinical research in cutaneous biology and skin disease.
more...
Krishan Maggon 's curator insight, December 16, 2:07 AM

Journal of Investigative Dermatology (2015) 135, 31–38; doi:10.1038/jid.2014.295; published online 14 August 2014

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Denis Jullien1, Jörg C Prinz2 and Frank O Nestle3

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis

Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis | Immunology and Biotherapies | Scoop.it
From BioPortfolio: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Social Media and Healthcare
Scoop.it!

Social media for pharma – an expert’s view

Social media for pharma – an expert’s view | Immunology and Biotherapies | Scoop.it
Even with risks and regulations, pharma needs to engage with patients and learn more about them

Via Plus91
more...
Tambre Leighn's curator insight, December 15, 9:21 PM

As we say in coaching....meet them where they are. Most patients and caregivers are using social media to get educated and get support with healthcare challenges. Time for pharma to harness the power and use it for good with patient centered support services.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antigen delivery by virus-like particles for immunotherapeutic vacc... - PubMed - NCBI

Ther Deliv. 2014 Nov;5(11):1223-40. doi: 10.4155/tde.14.74.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from NeuroImmunology
Scoop.it!

Angiochem Publishes Data on ANG4043, a Brain-Penetrant Anti-HER2 Monoclonal Antibody for Treatment on Brain Metastases | Angiochem: Peptide-Antibody Conjugates that Cross the Blood Brain Barrier

RT @JFPariseau: Great new paper from investee company #Angiochem showing its platform can deliver antibodies to BBB http://t.co/cUfWYgeGfh
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Vast Majority of Life-Saving Cord Blood Sits Unused

Vast Majority of Life-Saving Cord Blood Sits Unused | Immunology and Biotherapies | Scoop.it
High costs keep patients from using stem cells harvested from umbilical cords
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Summary of the British Transplantation Society Guidelines fo... : Transplantation

Summary of the British Transplantation Society Guidelines fo... : Transplantation | Immunology and Biotherapies | Scoop.it
The British Transplantation Society “Guideline for Transplantation Management of the Failing Kidney Transplant” was published in May 2014. This is the first national guideline in this field.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Regulation of advanced therapy medicinal products will affect the practice of ... - Nature.com

Regulation of advanced therapy medicinal products will affect the practice of ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Ossianix › Science and Technology

Ossianix › Science and Technology | Immunology and Biotherapies | Scoop.it

Sharks are the most evolutionarily ancient animal species to possess an adaptive immune system similar to humans, including the production of antibodies against invading pathogens. These ancestral antibodies called IgNARs for Immunoglobulin New Antigen Receptors have a number of remarkable and unique properties. IgNARs evolved as heavy chain only antibodies without the associated light chains found in human antibodies. Their individual variable domains (known as VNARs) are highly soluble compared to the human variable domains, which on their own are generally insoluble and aggregate. Additionally, VNARs are particularly stable and bind antigens under conditions that match, which would disrupt the integrity of most mammalian antibodies. Furthermore, shark antibodies are believed to be particularly stable since they evolved under the high osmolarity of shark blood, which is maintained by the protein denaturant urea.


Only a very small region at the tip of an antibody directly binds to an antigen and sharks have evolved a unique way of engaging target antigens. The diversity of human antibodies is generated by a complex of two variable domains (VH and VL) each of which has three sites of contact called complementarity-determining regions (CDR 1-3). Thus, antibodies rely on contributions from up to 6 CDRs, which create a relatively flat surface of for antigen binding. By contrast, VNAR single domains of shark antibodies lack a CDR2 and concentrate diversity in an extended CDR3 loop supported by a smaller CDR1 that preferentially seeks out cavities and buried epitopes. Additionally, the position of disulfide bridges that affect the stability, flexibility and orientation of the CDR3 loop create diverse isoforms (called type I, II and IV) that can recognize a wide array of antigens.

 

VNARs are the smallest known immunoglobulin-based antigen binding domains that can have agonistic or antagonistic effects on their own. Their unique combination of structural and biophysical properties makes them attractive building blocks for drug discovery applications, particularly in situations where monoclonal antibodies have proven to be less than ideal. Such examples include perturbation of protein-protein interactions and for targeting difficult but important target classes such as transporters, ion channels and G protein-coupled receptors and cell-surface carbohydrates. A new generation of modular therapeutic agents can be custom built with innovative functions beyond the reach of classical antibodies for the treatment of a broad range of human diseases.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 17, 6:32 AM
Flexible Formatting Platform: The VNAR platform is very versatile and a wide array of novel therapeutic products with different valency and specificity options can be readily produced. Mono- or bivalent antigen binding molecules can be developed with different half-lives, depending on the therapeutic indication. Half-life extension of products can be readily achieved by using either a VNAR reactive with human serum albumin or the Fc domain from human IgG. Effector functions can also be engineered for reduced or enhanced cytotoxicity as required.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Plantibodies Could Pave the Road to Wellness - Newsweek

Plantibodies Could Pave the Road to Wellness - Newsweek | Immunology and Biotherapies | Scoop.it
Newsweek Plantibodies Could Pave the Road to Wellness Newsweek The “plantibody,” as this and other antibodies grown in plants have been dubbed by the handful of companies that develop them, is the product of decades of sky-high hopes and...

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

the dream of decades may decrease the costs of MoAbs?

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells- Nature.com

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory  T cells- Nature.com | Immunology and Biotherapies | Scoop.it
Abstract

CD4+CD25+ regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their activation status. Here we show that, in contrast to conventional anti-CD4 monoclonal antibodies (mAbs), the humanized CD4-specific monoclonal antibody tregalizumab (BT-061) is able to selectively activate the suppressive properties of Tregs in vitro. BT-061 activates Tregs by binding to CD4 and activation of signaling downstream pathways. The specific functionality of BT-061 may be explained by the recognition of a unique, conformational epitope on domain 2 of the CD4 molecule that is not recognized by other anti-CD4 mAbs. We found that, due to this special epitope binding, BT-061 induces a unique phosphorylation of T-cell receptor complex-associated signaling molecules. This is sufficient to activate the function of Tregs without activating effector T cells. Furthermore, BT-061 does not induce the release of pro-inflammatory cytokines. These results demonstrate that BT-061 stimulation via the CD4 receptor is able to induce T-cell receptor-independent activation of Tregs. Selective activation of Tregs via CD4 is a promising approach for the treatment of autoimmune diseases where insufficient Treg activity has been described. Clinical investigation of this new approach is currently ongoing.


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

a functionnal cellular specificity? a major breakthrough?

more...
Krishan Maggon 's curator insight, December 17, 7:19 AM

Immunology and Cell Biology advance online publication 16 December 2014; doi: 10.1038/icb.2014.102

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
OPEN

Bianca Helling1, Martin König1, Benjamin Dälken1, Andre Engling1, Wolfgang Krömer1, Katharina Heim1, Holger Wallmeier2, Jürgen Haas3, Brigitte Wildemann3, Brigitte Fritz3, Helmut Jonuleit4, Jan Kubach4, Theodor Dingermann5, Heinfried H Radeke6, Frank Osterroth1, Christoph Uherek1, Niklas Czeloth1,7 and Jörg Schüttrumpf1,7

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Abzena/Polytherics - Antibody Drug Conjugates

Abzena/Polytherics - Antibody Drug Conjugates | Immunology and Biotherapies | Scoop.it

PolyTherics has developed its range of novel ThioBridge™ linkers to efficiently conjugate drugs to antibodies to create less heterogeneous ADCs with better stability. Our proprietary technology uses site-specific conjugation to naturally occurring inter-chain disulfides avoiding the need for antibody re-engineering to create a site of attachment.

We offer a range of cytotoxic payloads with different mechanisms of action which we can conjugate to your antibody using our ThioBridge™ technology. These payloads have been developed internally or are accessed through our partnerships.

PolyTherics can undertake the conjugation and analytical characterisation of the ADC in its own laboratories or provide a ThioBridge™ precursor reagent to you to use in-house. In addition to producing ADCs for potential therapeutic use, we can also produce antibody-conjugates for diagnostic & imaging purposes and ADCs using standard conjugation technologies for comparative purposes.

 

Optimisation of pharmacokineticsPolyTherics provides a range of site-specific conjugation technologies to optimise the pharmacokinetics (PK) and pharmacodynamics (PD) of therapeutic peptides and proteins, including antibody fragments and other protein scaffolds, by extending their half-life to reduce the frequency of dosing. This improves patient compliance and can reduce the cost of treatment. PolyTherics also provides a low viscosity polymer, PolyPEG™, to enable the easier injection of conjugated proteins which need to be administered at high concentration. 

Our proprietary PEGylation technologies enable polyethylene glycol (PEG) or other polymers to be attached to different specified sites depending on the nature of the protein. TheraPEG™ conjugates PEG at disulfide bonds, HiPEG™ conjugates PEG to poly-histidine motifs and CyPEG™ conjugates PEG to a thiol on a free cysteine. These technologies are used to conjugate both linear and branched PEG to therapeutic proteins and can be used for PolyPEG™ conjugation.

The conjugation processes are efficient, helping keep the cost of manufacture down, and the conjugated products are more stable and homogeneous than can be achieved with other well-established conjugation technologies.

We can PEGylate your protein or peptide in our laboratories or provide you with our conjugation reagents so you can undertake the work yourself. Our reagents are available in a range of PEG molecular weights and formats, including linear and branched PEGs.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 16, 6:25 AM

Humanized antibodies and deimmunised proteins are designed to be devoid of the T cell epitopes that lead to an adverse immune response while minimising the loss of antibody affinity or protein activity that can occur with standard protein engineering techniques.

 

 Composite Human Antibodies™
Antibody humanization technology is used to generate humanized and fully functional antibodies devoid of T cell epitopes in the variable region sequences to reduce immunogenicity in patients.  Composite Proteins™
Protein deimmunisation technology is used to generate therapeutic proteins devoid of human T cell epitopes to minimise potential immunogenicity in patients without compromising protein activity
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Biotherapeutics need general chapters not individual Ph. Eur. monographs says ... - BioPharma-Reporter.com

Biotherapeutics need general chapters not individual Ph. Eur. monographs says ... - BioPharma-Reporter.com | Immunology and Biotherapies | Scoop.it
Generic drugmakers want biotherapeutic products to have general recommendations in the European Pharmacopoeia rather than individual monographs.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

An update on primary findings and new designs in biotherapy studies for acute myocardial infarction, Future Cardiology, Future Medicine

An update on primary findings and new designs in biotherapy studies for acute myocardial infarction, Future Cardiology, Future Medicine | Immunology and Biotherapies | Scoop.it
An update on primary findings and new designs in biotherapy studies for acute myocardial infarction http://t.co/XpsksrxFdA
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Clinical applications of gamma delta T cells with multivalent immunity | T Cell Biology

Gamma delta T cells hold promise for adoptive immunotherapy because of their reactivity to bacteria, viruses, and tumors. However, these cells represent a small fraction (1-5%) of the peripheral T-...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

arGEN-X - SIMPLE Antibody™ Platform

arGEN-X - SIMPLE Antibody™ Platform | Immunology and Biotherapies | Scoop.it
arGEN-X - The SIMPLE Antibody™ platform is uniquely suited to therapeutic human antibody discovery.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 12, 2:37 AM

POTELLIGENT® enables monoclonal antibodies to be manufactured and produced in 100% fucose-free form, resulting in significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) and tumor cell-killing activity. POTELLIGENT® is exclusively licensed by BioWa, Inc., a member of the Kyowa Hakko Kirin Group.

We are applying POTELLIGENT® to our own and our partners’ antibody products under a non-exclusive license from BioWa.

POTELLIGENT® has been commercially validated by mogamulizumab (Poteligeo®), a defucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), developed by Kyowa Hakko Kirin and approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.

Aileenexa's curator insight, December 12, 6:02 AM

h65

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Cytotoxic T-lymphocyte antigen 4 gene polymorphism influence... : Pharmacogenetics and Genomics

Cytotoxic T-lymphocyte antigen 4 gene polymorphism influence... : Pharmacogenetics and Genomics | Immunology and Biotherapies | Scoop.it
BackgroundThe role of CTLA4 gene polymorphisms in T-cell-mediated immunity in association with human cytomegalovirus (HCMV) infection after transplantation is poorly understood.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Use of HBSAG Quantification To Guide HBIG Prophylaxis After Liver Transplantation - European Medical Journal

Use of HBSAG Quantification To Guide HBIG Prophylaxis After Liver Transplantation - European Medical Journal | Immunology and Biotherapies | Scoop.it
The European Medical Journal (EMJ) is an open-access, peer-reviewed medical journal. Founded in 2012 as an imprint of Gorely New Media, the European Medical Journal provides reviews, symposiums and developments from Europe's medical congresses.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Pembrolizumab induced durable responses in metastatic triple-negative breast cancer | Hematology Oncology

Pembrolizumab induced durable responses in metastatic triple-negative breast cancer | Hematology Oncology | Immunology and Biotherapies | Scoop.it
Hematology Oncology | The humanized anti–PD-1 antibody pembrolizumab induced durable responses in nearly 20% of heavily treated patients with metastatic, triple-negative breast cancer whose tumors expressed programmed cell death-ligand 1, according...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humanized PA14 (a monoclonal CCR5... [Cochrane Database Syst Rev. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.